Related references
Note: Only part of the references are listed.A Systematic Approach to Assess the Activity and Classification of PCSK9 Variants
Kepa B. Uribe et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants
Jacqueline S. Dron et al.
CURRENT OPINION IN LIPIDOLOGY (2017)
Evolutionary well-conserved region in the signal peptide of parathyroid hormone-related protein is critical for its dual localization through the regulation of ER translocation
Yoshihiro Amaya et al.
JOURNAL OF BIOCHEMISTRY (2016)
The p.Leu167del Mutation in APOE Gene Causes Autosomal Dominant Hypercholesterolemia by Down-regulation of LDL Receptor Expression in Hepatocytes
Ana Cenarro et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody
Paul N. Hopkins et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2015)
PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice
Anna Roubtsova et al.
JOURNAL OF LIPID RESEARCH (2015)
PCSK9 polymorphism in a Tunisian cohort: Identification of a new allele, L8, and association of allele L10 with reduced coronary heart disease risk
Afef Slimani et al.
MOLECULAR AND CELLULAR PROBES (2015)
The I-TASSER Suite: protein structure and function prediction
Jianyi Yang et al.
NATURE METHODS (2015)
GRP94 Regulates Circulating Cholesterol Levels through Blockade of PCSK9-Induced LDLR Degradation
Steve Poirier et al.
CELL REPORTS (2015)
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody
Paul N. Hopkins et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2015)
SILAC-based quantification of changes in protein tyrosine phosphorylation induced by Interleukin-2 (IL-2) and IL-15 in T-lymphocytes
Nerea Osinalde et al.
DATA IN BRIEF (2015)
PCSK9 acts as a chaperone for the LDL receptor in the endoplasmic reticulum
Thea Bismo Strom et al.
BIOCHEMICAL JOURNAL (2014)
Genetic diagnosis of familial hypercholesterolaemia by targeted next-generation sequencing
C. Maglio et al.
JOURNAL OF INTERNAL MEDICINE (2014)
Global Mass Spectrometry and Transcriptomics Array Based Drug Profiling Provides Novel Insight into Glucosamine Induced Endoplasmic Reticulum Stress
Ana Sofia Carvalho et al.
MOLECULAR & CELLULAR PROTEOMICS (2014)
Drug Sensing by the Ribosome Induces Translational Arrest via Active Site Perturbation
Stefan Arenz et al.
MOLECULAR CELL (2014)
Advantages and Versatility of Fluorescence-Based Methodology to Characterize the Functionality of LDLR and Class Mutation Assignment
Aitor Etxebarria et al.
PLOS ONE (2014)
Molecular basis for erythromycin-dependent ribosome stalling during translation of the ErmBL leader peptide
Stefan Arenz et al.
NATURE COMMUNICATIONS (2014)
APOE p.Leu167del mutation in familial hypercholesterolemia
Zuhier Awan et al.
ATHEROSCLEROSIS (2013)
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2013)
Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with the APOE p.Leu167del Mutation
Marie Marduel et al.
HUMAN MUTATION (2013)
Apolipoprotein E gene mutations in subjects with mixed hyperlipidemia and a clinical diagnosis of familial combined hyperlipidemia
Maria Solanas-Barca et al.
ATHEROSCLEROSIS (2012)
Molecular characterization of familial hypercholesterolemia in Spain
Lourdes Palacios et al.
ATHEROSCLEROSIS (2012)
Role of ubiquitination in PCSK9-mediated low-density lipoprotein receptor degradation
Yanqun Chen et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
I-TASSER: a unified platform for automated protein structure and function prediction
Ambrish Roy et al.
NATURE PROTOCOLS (2010)
Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants
Matthew J. Bottomley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation EVIDENCE FOR AN INTRACELLULAR ROUTE
Steve Poirier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa
Vivienne M. Homer et al.
ATHEROSCLEROSIS (2008)
I-TASSER server for protein 3D structure prediction
Yang Zhang
BMC BIOINFORMATICS (2008)
Molecular basis for LDL receptor recognition by PCSK9
Hyock Joo Kwon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
A PCSK9 variant and familial combined hyperlipidaemia
M. Abifadel et al.
JOURNAL OF MEDICAL GENETICS (2008)
Molecular code for transmembrane-helix recognition by the Sec61 translocon
Tara Hessa et al.
NATURE (2007)
Protein translocation across the eukaryotic endoplasmic reticulum and bacterial plasma membranes
Tom A. Rapoport
NATURE (2007)
Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells
Markey C. McNutt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation
Da-Wei Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly
Oystein L. Holla et al.
BMC CELL BIOLOGY (2007)
The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population
P Yue et al.
HUMAN MUTATION (2006)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis
SN Chen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment
KN Maxwell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia
TP Leren
CLINICAL GENETICS (2004)
NARC-1/PCSK9 and its natural mutants -: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol
S Benjannet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):: Liver regeneration and neuronal differentiation
NG Seidah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Share Paper
